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Abstract
The human reduced folate carrier (RFC) is the major membrane transport system for both reduced folates and chemotherapeutic antifolate
drugs, such as methotrexate (MTX). Although the RFC protein has been subjected to intensive study in order to identify critical structural and
functional determinants of transport, it is impossible to assess the significance of these studies without characterizing the essential domain
structure and membrane topology. The primary amino acid sequence from the cloned cDNAs predicts that the human RFC protein has 12
transmembrane domains (TMDs) with a large cytosolic loop between TMDs 6 and 7, and cytosolic-facing N- and C-termini. To establish the
RFC membrane topology, a hemagglutinin (HA) epitope was inserted into the individual predicted intracellular and extracellular loops. HA
insertions into putative TMD interconnecting loops 3/4, 6/7, 7/8, and 8/9, and the N- and C-termini all preserved MTX transport activity upon
expression in transport-impaired K562 cells. Immunofluorescence detection with HA-specific antibody under both permeabilized and non-
permeabilized conditions confirmed extracellular orientations for loops 3/4 and 7/8, and cytosolic orientations for loops 6/7 and 8/9, and the
N- and C-termini. Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln58
had minimal effects on MTX transport. Analysis of glycosylation status on Western blots suggested an extracellular orientation for loop 5/6,
and intracellular orientations for loops 8/9 and 9/10. Our findings strongly support the predicted topology model for TMDs 1–8 and the C-
terminus of human RFC. However, our results raise the possibility of an alternative membrane topology for TMDs 9–12.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The reduced folate carrier (RFC) is the transport system
for reduced folates, including 5-methyl and 5-formyl tetra-
hydrofolate (H4PteGlu), and antifolate drugs such as metho-
trexate (MTX) used for cancer chemotherapy [1,2]. The
carrier is considered to be ubiquitously expressed in tissues
and tumors and, by all indications, is the major folate
transport mechanism in mammals [1,2].
Since the RFC was originally cloned from mouse and
hamster cells in 1994 [3,4], and in human cells in 1995 [5–
8], there has been an intensive effort to identify the critical
structural and functional determinants of transport, using
random chemical [9] and site-directed mutagenesis [10–12],
or in vitro selection of drug-resistant cells with impaired
RFC activity [13]. An impressive number of amino acids
have been implicated as critical to RFC transport (numbers
refer to the human RFC or hRFC), including glycine-44
[14], glutamate-45 [13,15], serine-46 [16], isoleucine-48
[17], aspartate-88 [12], serine-127 [14], alanine-132 [18],
and arginines-133 [11,12] and -373 [11]. However, it is
nearly impossible to assess the functional significance of
these amino acids without a comprehensive model of RFC
membrane topology that depicts key structural and func-
tional domains including those comprising the putative
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transmembrane ‘‘channel’’ for membrane traverse of hydro-
philic folate and antifolate substrates.
In the original report of Dixon et al. [3], it was noted
that RFC conformed to a topology computer model simi-
lar that for the glucose carrier (GLUT1), with up to 12
transmembrane domains (TMDs), a large cytosolic loop
between TMDs 6 and 7, and cytosolic-facing N- and C-
termini (Fig. 1 depicts this topology model for hRFC). For
hRFC, glycosylation of asparagine-58 established this region
as extracellular [19]. Moreover, a hemagglutinin (HA) pep-
tide epitope (YPYDVPDYA) at the carboxyl terminus of
hRFC expressed in transport-impaired K562 cells was inac-
cessible to HA-specific antibody without membrane perme-
abilization, thus establishing this region as intracellular [19].
More recently, Ferguson and Flintoff [20] used HA inser-
tional mutagenesis and fluorescence staining to confirm
other critical features of this model, including the cytosolic
orientations of the amino terminus (proline-20) and the large
connecting loop between TMDs 6 and 7 (serine-225), and
an extracellular orientation for proline-297 in the connecting
loop between TMDs 7 and 8. However, many other key
features of the 12 TMD topology model have not been
directly assessed or could not be confirmed due to a loss of
hRFC expression and/or transport activity accompanying
insertion of the HA peptide epitope [20].
In this report, we expand upon our previous studies [19]
and those of Ferguson and Flintoff [20] in experimentally
confirming the membrane topology of hRFC. We use two
highly complementary experimental strategies including (i)
HA insertion mutagenesis and immunofluorescence staining
with HA-specific antibody in permeabilized and non-per-
meabilized cells, essentially as in these earlier studies
[19,20], and (ii) scanning glycosylation insertion mutagen-
esis of the non-glycosylated hRFC-Gln58 [19], followed by
Western blotting to confirm glycosylation status. Although
our results strongly support the predicted topology for
TMDs 1–8 in hRFC (Fig. 1), our results raise the possibility
of an alternative membrane topology for TMDs 9–12.
2. Materials and methods
2.1. Reagents
[3V,5V,7-3H] MTX (20 Ci/mmol) was purchased from
Moravek Biochemicals (Brea, CA). Unlabeled MTX was
provided by the Drug Development Branch, National Can-
cer Institute, Bethesda, MD. Both labeled and unlabeled
MTX were purified by HPLC prior to use [21]. Restriction
and modifying enzymes were obtained from Promega
(Madison, WI) or Roche (Indianapolis, IN). Synthetic oli-
gonucleotides were obtained from Invitrogen (Carlsbad,
CA). Tissue culture reagents and supplies were purchased
from assorted vendors with the exception of iron-supple-
mented calf serum, which was from Hyclone Laboratories,
Inc. (Logan, UT).
2.2. Cell culture
The MTX transport-deficient K500E subline was
selected from wild-type K562 (American Type Culture
Collection) and maintained in RPMI 1640 medium (Life
Technologies, Inc.) containing 10% calf serum, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 Ag/ml streptomy-
cin, with 0.5 AM of MTX [19]. K500E cells were trans-
fected with the wild-type (KS43) hRFC cDNA in pCDNA3
(designated pC43) to generate the K43-6 subline [22], with
the hRFC-Gln58 in pCDNA3 (designated DG9) to generate
KEDG9 cells [19], or with an hRFC construct including a
carboxyl-terminal HA insertion in pCDNA3 (designated
hRFC-HA12 in the present study) to generate K43HA12 cells
(previously called HA8) [19]. All hRFC transfectants were
Fig. 1. Computer-predicted topology structure of the hRFC protein. A topology model for hRFC is shown depicting 12 TMDs (numbered 1–12), internally
oriented amino and carboxyl termini, and an externally oriented N-glycosylation site at asparagine-58. The location of the HA- and N-glycosylation (GLYn)
consensus insertions are indicated. The positions of these modifications are summarized in Tables 1–3. The solid circles designate conserved charged residues
located in predicted TMD regions of hRFC and include asparate-88 (TMD2), arginine-133 (TMD4), and arginine-373 (TMD10).
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cultured in complete RPMI 1640 medium plus 1 mg/ml
G418 in a humidified atmosphere at 37 jC in the presence
of 5% CO2.
2.3. Site-directed mutagenesis
Two methods were used for site-directed mutagenesis.
(i) For the hRFC-HA3-11 constructs, a PCR-based muta-
genesis kit (ExSitek, Stratagene) was used to insert a
peptide including the HA epitope (YPYDVPDYAVN) into
designated sites of hRFC (these are noted in Fig. 1 and
summarized in Table 1). The VN residues were added to
generate a unique HpaI site (GTTAAC) in this series of
constructs in order to confirm the presence of the HA
peptide insertion. A highly processive polymerase, ExSitek
DNA polymerase (Stratagene), was used to eliminate pos-
sible random mutations induced by PCR. The full-length
KS43 hRFC cDNA in pBluescript SK() (pKB43) [6] was
amplified using the primers summarized in Table 1, follow-
ing the procedure provided by the manufacturer. Insertion of
the HA epitope was screened by either PCR, with primers
specific for HA (HAtag, 5Vtacccatacgatgttccggattacgct3Vor
rHAtag, 5Vagcgtaatccggaacatcgtatgggta3V), or by HpaI diges-
tion (see above). The hRFC-HA3-11 inserts were cloned
into pCDNA3 at the KpnI and XbaI sites.
(ii) ‘‘Splicing by Overlap Extension’’ (SOE) PCR [23]
was used to prepare hRFC-HA1 and -HA2 constructs and the
N-glycosylation mutants (hRFC-GLY5, -GLY8, -GLY9,
-GLY10, -GLY11), using the complementary PCR primers
shown in Tables 1 and 2. For the HA insertion mutants, wild-
type pC43 was used as template; for the glycosylation
insertion mutants, the deglycosylated DG9 form of hRFC,
with glutamine-58 replacing asparagine-58, in pCDNA3
[19] was used as template. For the hRFC-HA1, -HA2, and
-GLY5, two PCR steps were initially performed to amplify
two separate products, using the forward mutation
primer (Primer 2) and the rHA-7 reverse primer
(5Vctcgttccacaggatgtgcac3V; positions 882 to 862 relative to
start codon ATG where A is number 1), and the reverse
mutation primer (Primer 1) and p8 forward primer
(5Vcagtgtcaccttcgtcccctccg3V; positions 46 to 24). PCR
conditions for the primary PCR reactions were 94 jC for 30
s, 56 jC for 30 s, and 72 jC for 60 s for 35 cycles. Secondary
PCR was performed with the p8/rHA-7 primers and mixed
primary PCR products as templates, using the same con-
ditions as for the primary PCRs. The same strategy and
PCR conditions were used to generate hRFC-GLY8,
-GLY9, -GLY10, and -GLY11 mutations, however, KS2
(5Vcgcagcctcttcttcaaccgc3V; positions 622 to 642) and
RFCout12 (5Vgacaaccccttccccctgcactctgt3V; positions 1647
to 1619) primers were used with mutation primers 1 and 2,
respectively (Table 2), for the primary PCR reactions.
Secondary PCRs were performed with the KS2/RFCout12
primers. For subcloning the hRFC-HA1, -HA2, and hRFC-
GLY5 mutant constructs, the secondary PCR products were
digested with BbrPI/NotI, purified, and ligated into the
BbrPI/NotI-digested pC43 or DG9 vectors, as appropriate,
for transformation. NotI/SfiI restriction sites were used to
subclone the hRFC-GLY8, -GLY9, -GLY10, and -GLY11
(both -ins and -sub constructs) PCR products into digested
DG-9 vector. All mutant hRFC constructs were confirmed by
automated sequencing at the Center of Molecular Genetics
sequencing facility (Wayne State University).
Mutant constructs (5 Ag) were stably transfected into
K500E cells with Lipofectin (Life Technologies). Mutant
clones were selected for growth in 1 mg/ml G418 and
isolated from 0.35% soft agar for expansion and screening.
These methods are identical to those described in our
previous report [19].
2.4. Western analysis of hRFC
Plasma membranes were prepared and membrane pro-
teins were solubilized in 10 mM Tris–HCl, pH 7.0, with
proteolytic inhibitors [24]. Aliquots were electrophoresed
on 7.5% polyacrylamide gels in the presence of SDS [25]
Table 1
PCR primers for hRFC mutant constructs with HA insertions
hRFC-HAa Insertion sitesb Primer 1c Primer 2d
1 G17–P18 5VZcccaggttccacgggcacctgctt3V 5VXcctgaccccgagctccggtcctgg3V
2 Y92–T93 5VZgtagcgcaggtagtcggtgag3V 5VXacgccggtgctgctgctgcag3V
3 Q120–L121 5Vctgcatgtgcgccaccgagtg3V 5VXctcatggagctcttctacagc3V
4 G154–Y155 5Vgccggccacacgctggtagcgcgcgg3V 5VXtactcgcgcgctgcggtgctgctgggcgtg3V
5 S183–T184 5Vggagaaggagactcggcccac3V 5VXacgctcaactacatctcgctg3V
6 E226–L227 5Vctccgaagccgaggtttcgca3V 5VXctggagcgcatgaatcccggc3V
7 E294–V295 5Vctcgttccacaggatgtgcac3V 5VXgtggaccccaccaccaacagtg3V
8 A332–R333 5Vcgcccagcggatcttcacgaa3V 5VXcgctggtccaagctgctcatc3V
9 T356–R357 5Vcgtgtgcgccagaaggaagaccagccccg3V 5VXcgccacccgagcagcatctggctgtgcta3V
10 Q386–I387 5Vctgaaaggtggcgatgggcac3V 5VXattgcatcttctctgtctaaa3V
11 L426–P427 5Vgaggcccaggccccgcacgtc3V 5VXccggtccgcaagcagttccag3V
a hRFC-HA constructs 1–11, as described in the text.
b Location of HA-VN (YPYDVPDYAVN) epitope insertion in hRFC primary sequence.
c Antisense primer where ‘‘Z’’ corresponds to gtt aac agc gta atc cgg aac atc gat.
d Sense primer where ‘‘X’’ corresponds to atc gat gtt ccg gat tac gct gtt aac.
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and electroblotted onto PVDF membranes (Pierce) [26].
hRFC proteins were detected by enhanced chemilumines-
cence (Roche) with protein A-purified hRFC-specific anti-
body generated in rabbits with a glutathione S-transferase
(GST)-hRFC fusion protein [14].
2.5. Immunofluorescence microscopy
The orientations of HA epitope in assorted hRFC-HA
proteins in transfected cells were determined by immuno-
fluorescence using the HA-specific rhodamine-conjugated
12CA5 antibody (Roche). Non-permeabilized cells were
first incubated with rhodamine-conjugated 12CA5 in RPMI
1640 medium, containing 10% calf serum, 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 Ag/ml streptomycin for 1
h at 4 jC. The cells were fixed in 3.3% paraformaldehyde in
PBS for 30 min on ice. For permeabilization, cells were
washed with ice-cold PBS twice and resuspended in 1 ml of
3.3% paraformaldehyde and fixed for at least 30 min on ice.
Cells were then treated with 0.1% Triton X-100 in PBS for 5
min on ice, washed twice with large volumes (f15 ml) of
PBS, and then blocked with 1% BSA in PBS for 1.5 h at 4
jC. Cells were incubated in 200 Al PBS containing 5 Ag/ml
of rhodamine-conjugated 12CA5 antibody and 1% BSA for
1 h at 4 jC. Both permeabilized and non-permeabilized cells
were washed three times with PBS. Cells were cytocentri-
fuged onto microscope slides, mounted with ‘‘SlowFade’’
antifade reagent (Molecular Probes) and sealed with cover
slips. Immunofluorescence microscopy was performed with
an Olympus BX40 fluorescence microscope using an Uplan
F1 40/0.75 object lens. Pictures were taken by a Sony
DXC-970MD 3CCD color video camera connected to an
NEC Express 5800 computer for image visualizing.
2.6. Membrane transport measurements
Initial rates of [3H]-MTX (0.5 AM) uptake were meas-
ured over 180 s, as previously described [6,12,22]. Levels of
intracellular radioactivity were expressed as picomoles per
milligram of protein, calculated from direct measurements
of radioactivity and protein contents of the cell homoge-
nates. Protein assays were performed with the method of
Lowry et al. [27].
3. Results
3.1. Expression of hRFC-HA and hRFC-GLY constructs in
transport-impaired K562 cells
A computer-generated topology model based on the
predicted hRFC amino acid sequence is shown in Fig. 1.
The hydropathy analysis (‘‘TMPRED’’; [28]) for hRFC
predicts a model expected for an integral membrane protein
with up to 12 stretches of 17–25 mostly hydrophobic, alpha
helix-promoting amino acids (Fig. 1). In support of this
model are the findings that asparagine-58 was glycosylated
[22], and that a carboxyl terminal HA-tag (i.e., hRFC-
HA12) was not accessible to 12CA5 antibody labeling
without membrane permeabilization [19,20]. Other features
of this model have been confirmed by HA insertion muta-
genesis and immunofluorescence staining [20], and include
cytosolic orientations of the amino terminus (proline-20)
and the large connecting loop between TMDs 6 and 7
(serine-225), and an extracellular orientation for proline-
297 in the connecting loop between TMDs 7 and 8.
To verify features of this model that were not previously
assessed or could not be confirmed, two complementary
approaches were used. (i) HA epitopes were inserted into
the predicted loops connecting TMDs in hRFC to generate
the hRFC-HA2, hRFC-HA3, hRFC-HA4, hRFC-HA5,
hRFC-HA8, hRFC-HA9, hRFC-HA10, and hRFC-HA11
constructs (Fig. 1 and Table 1). Constructs hRFC-HA1,
hRFC-HA6, hRFC-HA7, and hRFC-HA12 (Fig. 1) were
also prepared, essentially corresponding to those reported by
Ferguson and Flintoff [20] to restore hRFC transport activity
in transfected Chinese hamster ovary cells. (ii) Scanning N-
glycosylation insertion mutagenesis (Table 2) was used with
the hRFC DG-9 construct encoding hRFC-Gln58 [19] to
generate hRFC-GLY2, hRFC-GLY4, hRFC-GLY5, hRFC-
Table 2
N-Glycosylation mutation primers
hRFC-GLYa Insertion siteb Primer 1c Primer 2d
2 R91–N–Y92 5Vcagcaccggcgtgtagttgcgcaggtagtc3V 5Vaccgactacctgcgcaactacacgccggtgctg3V
4 G154N 5Vcgcagcgcgcgagtcgttggccacacgatggta3V 5Vtaccaacgtgtggccaactactcgcgcgctgcg3V
5 F182N 5Vgtagttgagcgtggagttggagactcggcccac3V 5Vgtgggccgagtctccaactccacgctcaactac3V
8 R333N 5Vgagcagcttggaccagttcgcccagcggatctt3V 5Vaagatccgctgggcgaactggtccaagctgctc3V
9 H358N 5Vccagatgctgctcgggttgcgcgtgtgggccag3V 5Vctggcccacacgcgcaacccgagcagcatctgg3V
10 I387N 5Vagacagagaagatgcattctgaaaggtggcgat3V 5Vatcgccacctttcagaatgcatcttctctgtct3V
11sube PVRK430NNST 5Vgaactgactagtgttgttgaggcccaggccccgcacgtc3V 5Vggcctcaacaacactagtcagttccagttatactccgtg3V
11inse V428–NNST–R429 5Vcttgcgactagtgttattgaccgggaggcccaggcccc3V 5Vccggtcaataacactagtcgcaagcagttccagttatac3V
a hRFC-GLY constructs, as described in the text.
b Location of N-glycosylation [NX(S/T)] concensus sequence in the hRFC primary sequence.
c Antisense primer.
d Sense primer.
e In GLY11sub, residues PVRK (positions 427–430) were substituted by NNST, whereas in GLYins, NNST was inserted after position 428.
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GLY8, hRFC-GLY9, hRFC-GLY10, and hRFC-GLY11sub
[19]. As previously reported, replacement of the consensus
N-glycosylation site at asparagine-58 with glutamine had no
adverse effect on plasma membrane targeting or transport
function of hRFC [19].
The mutant constructs were all transfected into transport-
impaired K562 human cells (K500E), characterized by a
nearly complete loss of hRFC protein and MTX transport
[29]. Stable transfectants (designated K43HAn and K43GLYn,
for the series of HA-tagged and GLY-insertion constructs,
respectively) were selected in G418 selection medium, and
clonal populations expanded and screened on Western blots
with hRFC-specific antiserum.
Fig. 2A and B show that all mutants, with the exception
of K43HA2, expressed high levels of hRFC protein. For all
of the HA-tagged constructs, hRFC migrated as a broadly
banding species centered at f85 kDa (Fig. 2A). However,
among the expressed hRFC-GLY constructs, the pattern of
protein banding differed and either resembled that for the
glycosylated wild-type protein in K43-6 cells (for hRFC-
GLY5 and -GLY10) or the deglycosylated carrier in KEDG9
cells (for hRFC-GLY8, 9, and 11sub) [19] (Fig. 2B).
Mutants hRFC-GLY2 (R91–N–Y92) and hRFC-GLY4
(G154N) failed to produce detectable hRFC protein on
western blots (data not shown). Thus, the vast majority of
HA- and N-glycosylation insertions did not significantly
interfere with hRFC expression or plasma membrane target-
ing. The lack of expression with hRFC-HA2, hRFC-GLY2,
and hRFC-GLY4 proteins likely reflects misfolding of the
mutant proteins resulting in increased rates of degradation
[14,30].
All of the expressed hRFC forms were tested for trans-
port activity using 3H-MTX as substrate for comparison
with non-transfected K500E cells, and K43HA12 (expresses
carboxyl HA-tagged hRFC) and K43-6 (expresses wild-type
hRFC) cells, both of which exhibit high levels of 3H-MTX
transport [19,22]. For the series of hRFC-HA constructs,
including hRFC-HA1, -HA3, -HA6, -HA7, and -HA8,
MTX transport was increased over that in hRFC-null
K500E cells and was 20–60% of that in K43HA12 cells
(Fig. 3A). However, for hRFC-HA4, -HA5, -HA9, -HA10,
Fig. 3. Rates of 3H-MTX transport in K562 transfectants expressing wild-
type and mutant hRFC-HA and hRFC-GLY proteins. 3H-MTX (0.5 AM)
uptakes were measured for 180 s at 37 jC. Panel A shows data for hRFC-
HA transfectants and panel B shows uptake rates for the hRFC-GLY
transfectants. For comparison, transport data are shown for wild-type hRFC
transfectants (i.e., K43-6) and hRFC-Gln58 transfected cells (KEDG9). For
this series of experiments, hRFC-GLY11 refers to the GLY11sub mutation,
as described in Table 2. All transport results are the mean values of three to
four separate experiments (FS.E.).
Fig. 2. Expression of hRFC-HA and -GLY mutant constructs in transport-
impaired K562 cells. Data are shown for a Western blot of plasma
membrane proteins from hRFC-deficient K500E cells and K500E trans-
fectants expressing wild-type hRFC (K43-6) and mutant hRFCs including
hRFC-HA1 through -HA12 (panel A), and hRFC-GLY5 through -GLY11
(panel B). In the right portion of panel B are shown results for the migration
of the deglycosylated hRFC-Gln58 construct (KEDG9 cells) for comparison
with the wild-type hRFC construct in K43-6 cells. hRFC-GLY11 refers to
the GLY11sub mutation, as described in Table 2. Twenty micrograms of
protein from each sample were separated on a 7.5% gel in the presence of
SDS and electroblotted onto a PVDF membrane. Detection was with anti-
hRFC antibody and enhanced chemiluminescence. Molecular weight
standards (in kDa) are shown.
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and -HA11, levels of 3H-MTX uptake were not significantly
different from that in K500E cells.
For the hRFC-GLY series of transfectants, high levels of
MTX transport were, likewise, detected for K43GLY5
(hRFC-GLY5), K43GLY8 (hRFC-GLY8), and K43GLY9
(hRFC-GLY9) cells (Fig. 3B). Transport in K43GLY10 cells
(hRFC-GLY10) was indistinguishable from that in K500E
cells. Two hRFC-GLY11 mutant constructs were generated,
one (hRFC-GLY11sub) in which the N-glycosylation con-
sensus sequence NNST replaced four non-conserved amino
acids (P427VRK) in the middle part of the TMD 11/12
connecting loop and another (hRFC-GLY11ins) in which
NNST was inserted into the middle part of loop 11 between
positions V428 and P429. Both constructs were expressed, yet
neither was functional for MTX transport (the data in Figs. 2
and 3 are for the hRFC-GLY11sub).
3.2. Analysis of HA epitope membrane orientation in hRFC-
HA mutant proteins by immunofluorescence microscopy
Stable transfectants with high level expression of func-
tional HA epitope-tagged hRFCs were assayed by immuno-
fluorescence staining with rhodamine-conjugated 12CA5
antibody with and without membrane permeabilization,
essentially as described by Ferguson and Flintoff [20].
Without permeabilization, fluorescence should be detectable
in transfectants expressing hRFC-HA constructs for which
the HA tag was localized on the outside (extracellular)
surface of cells. However, when the HA tag was localized
to the inside (cytosolic) face, permeabilization would be
necessary to detect the fluorescent antibody complex.
Data are shown in Fig. 4 for transfected cells expressing
the functional hRFC-HA1, -HA3, -HA6, -HA7, -HA8, and
-HA12 constructs, along with that for mock-transfected
K500E cells as a negative control. Fluorescence was de-
tected in all permeabilized cells (denoted with ‘‘p’’ as in
‘‘HA1p’’), with the exception of K500E cells, thus demon-
strating good accessibility and reactivity of 12CA5 antibody
to the membrane-localized HA-tagged hRFC proteins.
For hRFC-HA3 and -HA7, the HA epitopes were clearly
extracellular since fluorescence was detectable without per-
meabilization. However, for hRFC-HA1, -HA6, -HA8, and
-HA12, permeabilization was essential to detect the HA
epitope (Fig. 4), demonstrating a lack of accessibility to
antibody and a probable cytosolic orientation for the HA
epitope.
3.3. Topology mapping by analysis of glycosylation patterns
in hRFC glycosylation insertion mutants
Scanning glycosylation mutagenesis, in which an N-
glycosylation [NX(S/T)] consensus sequence is inserted at
different sites along a primary sequence, has been success-
fully used for epitope mapping of integral membrane
proteins [31]. The underlying premise behind this approach
involves the notion that glycosylation occurs exclusively on
the luminal side of endoplasmic reticulum (ER) membranes
[32]. Once the protein is transported to the plasma mem-
brane, the luminal side of the ER corresponds to the
extracellular face of the protein so that the presence of an
N-linked oligosaccharide at a particular NX(S/T) consensus
sequence establishes its extracellular orientation.
For hRFC, glycosylation resulted in a marked shift in
banding on Western blots from thef65 kDa for the hRFC-
Gln58 construct expressed in KEDG9 cells [19] to a broadly
migrating band centered at f85 kDa for wild-type hRFC
Fig. 4. Detection of HA epitope-tagged hRFC proteins by immunofluorescence staining. Mock- and transport-competent hRFC-HA-transfected K500E cells
were incubated with rhodamine-conjugated anti-HA antibody (12CA5) with (‘‘p’’ as in HAnp) or without pretreatment with Triton X-100, as described in the
text.
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in K43-6 cells (Fig. 2B). Both hRFC-GLY5 and -GLY10
were glycosylated on Western blots, establishing extracel-
lular orientations for the glycosylation consensus sequences
inserted at positions 182 and 387. However, only hRFC-
GLY5 was functional (Fig. 3). hRFC-GLY5 and hRFC-
GLY10 could be enzymically deglycosylated to their 65
kDa forms by N-glycosidase F (data not shown). The lack
of glycosylation for hRFC-GLY8 and hRFC-GLY9 (Fig.
2B) is consistent with an intracellular orientation for posi-
tions 333 and 358.
4. Discussion
Hydropathy analysis of RFC from both humans and
rodents has resulted in a topology model involving up to
12 TMDs, symmetrically grouped around a large central
loop with internally oriented amino- and carboxyl termini
[1,3,20]. In this study, we performed a systematic inves-
tigation of hRFC membrane topology in an attempt to verify
this model. We employed two highly complementary
approaches, HA insertion mutagenesis and immunofluores-
cence staining with HA-specific antibody in permeabilized
and non-permeabilized human transfectants, and scanning
glycosylation insertion mutagenesis of the non-glycosylated
hRFC-Gln58 construct, followed by Western blotting to
confirm glycosylation status and probable membrane ori-
entation. We focused primarily on functional hRFC con-
structs in our analysis to exclude any significant bias that
may result from misfolded non-functional proteins.
Both HA-epitope insertion and scanning glycosylation
mutagenesis have been used to characterize the membrane
topologies for a number of integral membrane proteins
including the glycine transporter [33], human glucose 6-
phosphate transporter [34], Band 3 anion exchanger [31],
mouse P-glycoprotein [35], and Na+K+ ATPase [36]. More-
over, for hRFC, HA insertion mutagenesis was used to
establish the topologies for the N- and C-termini, and the
connecting loops between TMDs 6 and 7, and between
TMDs 7 and 8 [19,20]. The present results strongly support
the computer-predicted topology model for TMDs 1–8 (Fig.
1). However, the topology for TMDs 9–12 remains unset-
tled. Our findings are summarized in Table 3, and are
interpreted as follows.
4.1. TMDs 1–8 and central connecting loop
Insertion of the HA epitope at glycine-17 caused no
adverse effects on hRFC expression and function. The
resulting hRFC-HA1 protein was inaccessible to 12CA5
antibody without permeabilization, confirming the cytosolic
orientation of the N-terminal HA epitope, as previously
reported [20]. Our earlier finding that hRFC is glycosylated
at asparagine-58 [19] established an extracellular orientation
for the connecting loop between putative TMDs 1 and 2.
While hRFC-HA2 (HA insertion at tyrosine-92) could not
be stably expressed in K500E cells, hRFC-HA3 (insertion at
glutamine-120) was highly expressed and was competent
for MTX uptake. By immunofluorescence staining, the HA
orientation in hRFC-HA3 was unambiguously extracellular.
The insertion of the HA epitope at serine-183 in hRFC-HA5
abolished carrier activity, however, replacement of phenyl-
alanine-182 by asparagine in hRFC-GLY5 generated a new
N-glycosylation consensus site and resulted in the synthesis
Table 3
Summary of HA-epitope insertion and scanning N-glycosylation data
Numbera HA Insertion GLY Insertion Location Transportb Predictionc Experimentald
between
HA GLY HA GLY
1 G17–P18 N-terminus Y ND C C
2 Y92–T93 R91–N–Y92 TMD2/3 NE NE C – –
3 Q120–L121 TMD3/4 Y ND E E
4 G154–Y155 G154N TMD4/5 N NE C – –
5 S183–T184 F182N TMD5/6 N Y E – E
6 E226–L227 TMD6/7 Y ND C C
7 E294–V295 TMD7/8 Y ND E E
8 A332–R333 R333N TMD8/9 Y Y C C C
9 T356–R357 H358N TMD9/10 N Y E – C
10 Q386– I387 I387N TMD10/11 N N C – –
11sube L426–P427 PVRK430NNST TMD11/12 N N E – –
11inse V428–NNST–R429
12 Q587–N588 C-terminus Y ND C C –
Abbreviations: TMD, transmembrane domain; Y, yes; N, no; NE, not expressed; C, cytosolic; E, extracellular; NE, not expressed; ND, not determined.
a Numbers refer to HA or GLY constructs, as shown in Fig. 1.
b Transport activity was measured over 180 s with 0.5 AM MTX, as described in Materials and methods.
c Based on the 12-TMD model for hRFC topology depicted in Fig. 1.
d Experimentally determined topology by fluorescence staining (HA) or Western analysis (GLY) for the transport competent hRFC constructs, as described
in the text.
e In GLY11sub, residues PVRK (positions 427–430) were substituted by NNST. In GLYins, NNST was inserted after position 428.
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of a functional glycosylated hRFC protein. Thus, the loop
between TMDs 5 and 6 must be extracellular.
Similar to the results of Ferguson and Flintoff [20],
neither insertion of the HA epitope at glutamate-226 in the
loop connecting TMDs 6 and 7, nor at glutamate-294,
between TMDs 7 and 8, significantly interfered with hRFC
transport function. By immunofluorescence staining, these
regions mapped to the cytosolic and extracellular faces,
respectively. Finally, insertion of an HA epitope at alanine-
332 (in hRFC-HA8), between TMDs 8 and 9, preserved low
levels of transport activity and resulted in a pattern of
antibody reactivity consistent with a cytosolic orientation.
This interpretation was strengthened by the complete
absence of glycosylation in the highly active hRFC-GLY8
protein (replacement of arginine-333 by asparagine). Col-
lectively, these results support the predicted membrane top-
ology for TMDs 1–8 depicted in Fig. 1.
Additional evidence for the predicted topology model
involves loss of transport activity upon generation of ener-
getically unfavored ‘‘uncompensated’’ charged residues in
hydrophobic domains [37], by neutralizing one-half of a
charge pair [38–42]. For instance, replacement of aspartate-
88 and arginine-133 in hRFC by neutral amino acids,
individually (valine and leucine, respectively), abolished
transport [12]. However, their simultaneous replacement
restored activity, establishing their charge-pair stabilization
and probable localization in membrane-spanning domains
(TMDs 2 and 4, respectively, in Fig. 1).
4.2. TMDs 9–12 and carboxyl terminus
Interpretation of the topology for TMDs 9–12 is con-
founded by the lack of functional hRFC-HA9, -HA10,
-HA11, -GLY10, and -GLY11 proteins. hRFC-GLY9 and
hRFC-HA12 were both functional. hRFC-GLY9 was ungly-
cosylated, and hRFC-HA12 required permeabilization for
12CA5 antibody labeling, suggesting intracellular orienta-
tions for the connecting loop between TMD 9 and TMD 10,
and the carboxyl terminus. However, the surprising lack of
glycosylation of the TMD 9/10 loop in hRFC-GLY9 may
also reflect spacial considerations for which the N-glyco-
sylation consensus sequence may be simply too close to the
end of a transmembrane segment for proper N-glycosylation
by oligosaccharyl transferase [31]. By analogy with aspa-
rate-88/arginine-133 [12] (see above), the loss of transport
activity by neutralizing arginine-366 with leucine in murine
RFC (arginine-373 in hRFC; located in putative TMD 10 in
Fig. 1) [11] may involve the generation of an uncompen-
sated anionic residue in a hydrophobic domain.
These results are not easily reconciled with the computer-
predicted topology model (Model A, Fig. 5) for TMDs 7–
12 and are best explained by alternative models (Models B1
and B2, Fig. 5). For the latter, TMD 8 spans the plasma
membrane, as for Model A, yet both the original TMD 8/9
and TMD 9/10 connecting loops are intracellular. Although
the dispositions of the original TMDs 9 through 12 are not
completely certain, glutamate-373 in TMD 10 appears to be
buried (see above), leading us to depict TMD 10 as span-
ning the plasma membrane. It is of interest that models B1
and B2 both predict that position 387 in the original TMD
10/11 connecting loop has an extracellular orientation, given
the finding that asparagine-387 in hRFC-GLY10 was gly-
cosylated. However, hRFC-GLY10 was non-functional.
Since the carboxyl terminus of hRFC is intracellular, either
the original TMD 12 (model B1) or TMD 11 (model B2)
must also span the membrane.
Although both models B1 and B2 predict only 10 TMDs,
from the marked hydrophobicities of the original TMDs 9–
12, some degree of membrane association with all these
domains, nonetheless, seems likely. A ‘‘membrane embed-
ded’’ hydrophobic domain structure analogous to TMDs 9
and 11 in model B1, and TMDs 9 and 12 in model B2, was
described for the topology of the Alzheimer’s disease-
related presenilin 1 protein [43]. Moreover, similar mem-
brane localized ‘‘reentrant loop’’ structures were described
for the glutamate transporter family [44,45].
Further clarification of the membrane topology of hRFC
will undoubtedly require alternative experimental approaches
Fig. 5. Proposed models of hRFC topology for TMDs 7–12. Three topology schemes for hRFC are presented for TMDs 7–12. Model A is based on the 12
TMD model in Fig. 1. Alternative models B1 and B2 are based on the lack of glycosylation for asparagine-358 for hRFC-GLY9, suggesting that the original
TMD 9/10 connecting loop has an intracellular orientation, and the presumption of a membrane-spanning TMD 10 including arginine-373. These models are
further supported by the finding that asparagine-387 in hRFC-GLY10 is glycosylated, as described in the text. Models B1 and B2 differ by virtue of the
presence of membrane-spanning TMD 12 and TMD 11, respectively. For model B1, TMDs 9 and 11 (depicted by broken lines) are viewed as membrane-
embedded hydrophobic domains; for model B2, TMDs 9 and 12 (broken lines) are the membrane-embedded domains.
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(e.g., cysteine-scanning mutagenesis and reactivity with N-
biotinylaminoethyl methanethiosulfonate [46]). Clarification
of the membrane topology and domain structure of hRFC is
requisite to understanding the molecular mechanism of folate
and antifolate membrane transport.
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